Unicycive Therapeutics (UNCY) closed at $3.66 on November 10, 2026, down 1.1% from the previous close, on volume of 624,982 shares (30-day average 1,085,845).
Data as of November 10, 2026.
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Wed, 4-Nov 7:05 AM ET)
Business Wire (Mon, 2-Nov 12:35 PM ET)
Globe Newswire (Mon, 2-Nov 10:31 AM ET)
ACCESS Newswire (Fri, 30-Oct 10:15 AM ET)
Newsfile (Thu, 29-Oct 6:30 PM ET)
PRNewswire (Thu, 29-Oct 10:09 AM ET)
PRNewswire (Wed, 28-Oct 3:38 PM ET)
Business Wire (Tue, 27-Oct 4:30 PM ET)
Globe Newswire (Tue, 27-Oct 3:18 PM ET)
UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact SueWallSt
Globe Newswire (Tue, 27-Oct 10:16 AM ET)
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Unicycive Therapeutics trades on the NASDAQ stock market under the symbol UNCY.
As of November 11, 2026, UNCY stock price climbed to $3.74 with 406,215 million shares trading.
UNCY has a beta of 0.94, meaning it tends to be less sensitive to market movements. UNCY has a correlation of 0.04 to the broad based SPY ETF.
UNCY has a market cap of $104.18 million. This is considered a Micro Cap stock.
Last quarter Unicycive Therapeutics reported $0 in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-29 million and exceeded earnings estimates by $.27.
In the last 3 years, UNCY traded as high as $18.18 and as low as $2.02.
The top ETF exchange traded funds that UNCY belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
UNCY has underperformed the market in the last year with a return of -20.6%, while the SPY ETF gained +12.7%. In the last 3 month period, UNCY fell short of the market, returning -25.5%, while SPY returned -1.4%. However, in the most recent 2 weeks UNCY has outperformed the stock market by returning +3.6%, while SPY returned -1.2%.
UNCY support price is $3.49 and resistance is $3.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UNCY shares will trade within this expected range on the day.
